Overview

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Cardiac Safety Study
Phase:
Phase 2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.